Celularity

111 articles about Celularity

• Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

  4/15/2024

  Celularity Inc. today announced that its expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February for its advanced biomaterial products and biobanking businesses.

• Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsCompany Presenting at ASGCT Annual Meeting

  4/8/2024

  Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year’s American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.

• Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

  3/26/2024

  Celularity Inc. announced that the U.S. Centers for Medicare & Medicaid Services has granted a Healthcare Common Procedure Coding System Q code for Biovance® 3L, a tri-layer allograft derived from placental tissue intended for use as a biological membrane covering barrier or wrap that acts as a scaffold for restoration of functional tissue in partial- and full-thickness, acute and chronic wounds.

• Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

  3/20/2024

  Celularity Inc., a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that it has submitted a request to the U.S. Food and Drug Administration for orphan drug designation for its off-the-shelf, placental-derived cell therapy, PDA-002, for treating Facioscapulohumeral Muscular Dystrophy.

• Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

  3/14/2024

  Celularity Inc. announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present on the promise of cellular therapy to improve longevity at this year’s ABUNDANCE Summit on March 21, 2024.

• Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

  3/12/2024

  Celularity Inc. announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.

• Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

  3/7/2024

  Celularity Inc., a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced that it will present in vivo data from its T-cell therapy platform at this year’s AACR Annual Meeting.

• Celularity Announces 1-for-10 Reverse Stock Split

  2/23/2024

  Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of its Class A common stock, to be effective at 5:00 p.m. Eastern Standard Time, Wednesday, February 28, 2024.

• Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

  2/14/2024

  Celularity Inc. announced that its abstract “Tri-layer decellularized, dehydrated human amniotic membrane supports proliferation and stemness of limbal stem cells derived from induced pluripotent stem cells” has been accepted as a poster presentation at WBC 2024, the 12th World Biomaterials Congress which will be held on 26-31 May 2024 in Daegu, Republic of Korea, and hosted by the Korean Society for Biomaterials.

• Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

  2/1/2024

  Celularity Inc. announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline.

• Celularity Releases CEO Letter to Shareholders

  1/18/2024

  Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder.

• Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

  1/4/2024

  Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications.

• Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

  1/3/2024

  Celularity Inc. announced expected net sales of its advance biomaterial products and biobanking businesses for the fourth quarter 2023 and the full year 2023 and expected total revenue for the fourth quarter 2023 and the full year 2023.

• Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

  10/18/2023

  Celularity Inc. announced that its Halal Certified biomaterial products have been classified by the Saudi Food and Drug Authority as “Minimally Manipulated Biological Products” for importation license purposes in the Kingdom of Saudi Arabia.

• Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

  9/7/2023

  Celularity Inc. today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors.

• Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

  8/29/2023

  Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron) to support the research of Regeneron’s allogeneic cell therapy candidates.

• Celularity Inc. Announces $3 Million Registered Direct Offering

  7/27/2023

  Celularity Inc. today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock.

• Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

  7/27/2023

  Celularity Inc. and Verséa Ophthalmics, LLC today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Verséa Ophthalmics will distribute Celularity’s BIOVANCE® and BIOVANCE® 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications.

• Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

  7/18/2023

  Celularity Inc., a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced that it will present data on its proprietary extracellular matrices at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering, to be held on 24-26 July in Osaka, Japan.

• Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

  6/29/2023

  Celularity Inc. announced that the Company will present data from a new product technology in development for orthopedic applications at the upcoming 7th International Conference on Orthopedics, July 19th – 20th in Rome.